DYLOJECT (diclofenac sodium) by Inpharmus is mechanism of action diclofenac sodium extended-release tablets have analgesic, anti-inflammatory, and antipyretic properties. Approved for pain, postoperative pain, osteoarthritis and 4 more indications. First approved in 2014.
Drug data last refreshed 18h ago · AI intelligence enriched 2w ago
DYLOJECT is an intravenous diclofenac sodium solution approved in 2014 for acute pain management across multiple indications including postoperative pain, osteoarthritis, low back pain, and soft tissue injuries. It works by inhibiting cyclooxygenase (COX-1 and COX-2) enzymes to reduce prostaglandin synthesis, thereby decreasing pain, inflammation, and fever. The IV route provides rapid onset compared to oral NSAIDs, making it suitable for perioperative and acute care settings.
Product approaching LOE in March 2027 with only 0.9 years of exclusivity remaining; teams should anticipate downsizing or transition to generic support strategies.
Mechanism of Action Diclofenac sodium extended-release tablets have analgesic, anti-inflammatory, and antipyretic properties. The mechanism of action of diclofenac sodium extended-release tablets, like that of other NSAIDs, is not completely understood but involves inhibition of cyclooxygenase…
Worked on DYLOJECT at Inpharmus? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
A Study of Tirbanibulin Ointment and Diclofenac Sodium Gel for the Treatment of Adult Participants With Actinic Keratosis on the Face or Scalp
To Evaluate the Superiority of Fixed Combination (Orfenadrine 35mg, Acetaminophen 325mg, Caffeine 65mg and Diclofenac Sodium 50mg) Compared to Voltaren® (Diclofenac Sodium 50mg) in the Treatment of Acute Postural Low Back Pain.
A Randomized, Double-Blind, Parallel-Group, Vehicle-Controlled, Multicenter Study Comparing Diclofenac Sodium Gel, 3% to Solaraze® Gel, 3% in the Treatment of Actinic Keratosis on the Face or Bald Scalp
Efficacy and Safety of Ingenol Mebutate Gel 0.015% Compared to Diclofenac Sodium Gel 3% in Subjects With Actinic Keratoses on the Face or Scalp
Efficacy and Safety of Diclofenac Sodium Topical Gel 1% Compared to Placebo in Subjects With Acute Blunt Trauma Injuries
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/moPatent cliff in less than a year — expect lifecycle management and generic defense hiring
Working on DYLOJECT offers minimal career advancement opportunity given zero linked job openings and imminent LOE in March 2027. Professionals joining this product should view it as a transition role or short-term assignment focused on managing decline and generic transition, not growth or innovation.